Latest Headlines

Latest Headlines

UPDATED: Theravance rallies after FDA's mixed Breo briefing

As GlaxoSmithKline gears up for an advisory committee meeting on Breo, the British drug giant can expect to face questions about the efficacy of the inhaled once-daily combo of fluticasone furoate (FF) and vilanterol (VI).

UPDATED: Theravance: Biotech's big coming-of-age story

With two of its respiratory meds under review for potential approvals this year, Theravance stands to grow up significantly in 2013, giving more reasons for large pharma companies to come knocking. GlaxoSmithKline, Theravance's longtime lung drug partner and owner of 27% of the biotech's stock, rose again to the top of the list of potential acquirers in speculation this week. Read the full story >>

GSK rests hopes on R&D pipeline after tough 2012

GlaxoSmithKline faces some major regulatory decisions this year that will shape the future of the drug giant for years to come. And Bloomberg took the pulse of how industry watchers have harbored angst about the big year ahead for GSK and gathered insights from the company's pharma R&D boss, Patrick Vallance.

UPDATED: GSK and Theravance make progress in FDA review of key COPD drug

GlaxoSmithKline has made progress with one piece of the puzzle to maintain its dominance in the respiratory drug market.